Register for our free email digests:
Biosimilars
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Teva Sees COVID Sales Correction
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
Who’s Hired? ANI Names New CEO
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
FDA Updates ‘Purple Book’ Database
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Teva And Alvotech Strike US Biosimilars Pact
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.